Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Islet Sciences Inc.

www.isletsciences.com

Latest From Islet Sciences Inc.

The NASH Pipeline: Replete With Targets And New Compounds

The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.

Liver & Hepatic Market Intelligence

Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy

California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.

BioPharmaceutical United States

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

NASH Opportunity Spurs Deal-Making Flurry

Companies big and small are making deals and advancing candidates to address an unmet medical need thought to have a vast undiagnosed patient base in the U.S. and Europe.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Islet Sciences Inc.
  • Senior Management
  • James Green, Chmn. & CEO
    Steven Delmar, CFO
  • Contact Info
  • Islet Sciences Inc.
    Phone: (919) 480-1518
    8601 Six Forks Rd., Ste. 400
    Raleigh, NC 27615
    USA
UsernamePublicRestriction

Register